Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2024-01-28
Target enrollment:
Participant gender:
Summary
This early phase I trial studies the side effects and how well local consolidative therapy
(LCT) and brigatinib works in treating patients with non-small cell lung cancer that is stage
IV or has come back (recurrent). Giving LCT, such as surgery and/or radiation, after initial
treatment may kill any remaining tumor cells. Brigatinib may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth. Giving LCT and brigatinib may work
better in treating patients with non-small cell lung cancer.